Arthritis, Gouty - 19 Studies Found Completed : Celebrex In Acute Gouty Arthritis Study : Arthritis, Gouty : 2007-10-24 : Drug: Indomethacin indomethaci Recruiting : A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis : Acute Gouty Arthritis : 2016-12-13 : Drug: Anakinra 100 mg 100 mg/0 Completed : Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients : Acute Gouty Arthritis : 2011-05-16 : Drug: Canakinumab pre-filled syringe Completed : Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients : Acute Gouty Arthritis : 2011-08-30 : Drug: Canakinumab 150mg in prefilled syringe Canakinumab 150mg in prefilled syringe will be given in a s Completed : Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout : Arthritis, Gouty : 2008-04-18 : Biological: canakinumab 10 mg/ Withdrawn : Canakinumab in the Treatment of Gouty Arthritis Flare(s) and Prevention of New Flares in Patients With Chronic Kidney Disease : Acute Gouty Arthritis : 2012-05-03 : Drug: ACZ885 Canakinumab 150 m Recruiting : The Clinical Study on Treating Acute Gouty Arthritis Using Both Internal and External Therapy of Tonifying Spleen and Descending Turbid : Acute Gouty Arthritis : 2015-09-02 : Drug: diclofenac sodium enteric-coated Dru Completed : β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3) : Acute Gouty Arthritis Flares : 2011-08-16 : Drug: ACZ885 canakinumab 150 mg s.c., given on demand upon new flares Completed : Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective : Gouty Arthritis : 2011-05-24 : Drug: Canakinumab, ACZ885 Cana Withdrawn : Apremilast Therapy for Acute Gouty Arthritis : Acute Gout : 2009-10-09 : Drug: apremilast apremilast 20 Next >>>
